Biowaiver for Capecitabine - FDA x EMA [Dissolution / BCS / IVIVC]

posted by Mauricio Sampaio  – Brazil, 2015-09-08 22:38 (3123 d 21:31 ago) – Posting: # 15390
Views: 12,147

Why FDA indicates a possibility to request a Biowaiver for Capecitabine (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm083276.pdf) and EMA assumes that data on solubility does not allow the BCS classification of capecitabine (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500189272.pdf) ?

If both agencies are based on BCS classification from Amidon, who is correct? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
72 visitors (0 registered, 72 guests [including 2 identified bots]).
Forum time: 19:09 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5